Welcome to our dedicated page for PAND news (Ticker: PAND), a resource for investors and traders seeking the latest updates and insights on PAND stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PAND's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PAND's position in the market.
Merck (NYSE: MRK) has announced its agreement to acquire Pandion Therapeutics (Nasdaq: PAND) for $60 per share, totaling approximately $1.85 billion. The acquisition aims to enhance Merck's portfolio in autoimmune disease therapeutics, leveraging Pandion's TALON technology and its lead candidate, PT101. PT101 has completed a Phase 1a clinical trial focusing on safety and tolerability, showing promise in treating autoimmune diseases. The transaction is expected to close in the first half of 2021, pending regulatory approvals and other customary conditions.
Pandion Therapeutics (PAND) presented preclinical data on its PD-1 agonist PT001 at the nPOD Annual Scientific Meeting, indicating a delay in hyperglycemia onset in a Type 1 diabetes mouse model. The collaborative research with St Vincent’s Institute suggests that PT001 could enhance immune responses by activating PD-1 receptors in autoimmune disease contexts. The company aims to advance PT001's development while exploring additional pancreas-targeted therapies. The development candidate nomination for PT001 is expected in the first half of the year.
Pandion Therapeutics (Nasdaq: PAND) announced that CEO Rahul Kakkar will present at the 10th Annual SVB Leerink Healthcare Conference on February 25, 2021, at 9:20 a.m. ET. The presentation will be accessible via a live webcast on the company's website, with a replay available afterward.
Pandion is focused on developing innovative therapies for autoimmune diseases, using its TALON drug design platform to create treatments like PT101, which aims to enhance regulatory T cells while minimizing proinflammatory responses.
Pandion Therapeutics (Nasdaq: PAND) announced positive outcomes from its Phase 1a trial of PT101, indicating safety and significant regulatory T cell expansion, crucial for treating autoimmune diseases. The trial, involving 56 healthy volunteers, showed no serious adverse events and confirmed PT101's selectivity. The company plans to initiate a Phase 1b/2a trial for ulcerative colitis and a Phase 2 for systemic lupus erythematosus in mid-2021, following regulatory assessments. PT101 aims to selectively activate Tregs, potentially enhancing treatment efficacy for various autoimmune conditions.
Pandion Therapeutics (Nasdaq: PAND) has appointed Katina Dorton, J.D., M.B.A., as Chair of the Audit Committee. She brings over two decades of financial expertise, enhancing the board after the resignation of Mitchell Mutz, Ph.D. Dorton previously served as CFO at Repare Therapeutics and AVROBIO. CEO Rahul Kakkar expressed confidence in her ability to drive growth for the company, especially with the Phase 1a results for PT101 expected in early 2021. Pandion is focused on developing innovative treatments for autoimmune diseases using its TALON platform.
Pandion Therapeutics reported a successful enrollment and dosing completion in its Phase 1a clinical trial for PT101, anticipating top-line results in early 2021. The company nominated PT627 as its systemic PD-1 agonist candidate, with IND-enabling studies set to commence in 4Q 2020. Financially, Pandion raised approximately $153 million in its IPO, enhancing its cash position to $232.3 million as of September 30, 2020. However, the company reported a net loss of $11.9 million for Q3 2020, compared to $6.9 million in the same period last year.
Pandion Therapeutics (Nasdaq: PAND), a biotechnology firm focused on autoimmune disease treatments, has announced that CEO Rahul Kakkar, M.D. will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 4:00 p.m. ET. The presentation will be available via a live audio webcast on the company’s website, with a replay offered post-event. Pandion's primary product candidate, PT101, is currently undergoing a Phase 1a clinical trial. This candidate aims to expand regulatory T cells without triggering proinflammatory cells, reflecting the company's innovative approach in treating autoimmune conditions.
Pandion Therapeutics (Nasdaq: PAND) has presented preclinical data at FOCIS 2020 virtual meeting, showcasing its modular biologics pipeline aimed at treating autoimmune diseases. Their TALON platform enables the creation of targeted antibody-based therapies. Key findings include in vivo proof of concept for tethered immune effectors in gut and skin, as well as advancements in kidney research. Data highlighted the potential of PD-1 agonists and localized immune regulation, suggesting a novel approach to autoimmune therapy.
Pandion Therapeutics (Nasdaq: PAND) announced that CEO Rahul Kakkar will participate in a panel discussion at the Stifel Immunology & Inflammation Summit on October 1, 2020, at 3:00 p.m. ET. A live audio webcast of the discussion will be available on the company's investor website, with a replay accessible after the event.
Pandion focuses on developing novel therapeutics for autoimmune diseases, utilizing its TALON platform. Its lead product candidate, PT101, is currently undergoing a Phase 1a clinical trial, aimed at expanding regulatory T cells without activating pro-inflammatory cells.
Pandion Therapeutics, a clinical-stage biotechnology company focused on autoimmune diseases, has announced that CEO Rahul Kakkar will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020, at 2:00 p.m. ET. A live audio webcast will be available on Pandion's investor website, with a replay accessible for 90 days post-event. The company is advancing its TALON platform to develop immunomodulatory therapies, including its lead candidate PT101, currently in Phase 1a trials.
